Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions.Target Discovery, Research Collaboration and Option Agreement • March 5th, 2020 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations
The purpose of this letter (this “Letter Agreement”) is to memorialize our discussions and the agreement reached between Incyte and Syros with respect to certain issues related to the Target Discovery, Research Collaboration and Option Agreement between Incyte Corporation (“Incyte”) and Syros Pharmaceuticals, Inc., (“Syros”) dated January 8, 2018 (the “Agreement”). Capitalized terms not defined herein shall have the meanings set forth in the Agreement.
LICENSE AND COLLABORATION AGREEMENT by and between Syros Pharmaceuticals, Inc. and Global Blood Therapeutics, Inc. Dated as of December 17, 2019License and Collaboration Agreement • March 5th, 2020 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This License and Collaboration Agreement (this “Agreement”) is made as of December 17, 2019 (the “Effective Date”), by and between Syros Pharmaceuticals, Inc., a Delaware corporation (“Syros”), having its principal office at 35 CambridgePark Drive, Cambridge, MA 02140, and Global Blood Therapeutics, Inc., a Delaware corporation (“GBT”), having its principal office at 171 Oyster Point Blvd, Suite 300, South San Francisco, CA 94080. GBT and Syros are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
